Aflibercept, Faricimab Show Slightly Higher IOI Rates | Retina 2026

WAIKOLOA, Hawaii — Recent findings presented at Retina 2026 underscore the critical importance of ongoing postmarketing surveillance for newer ophthalmic treatments. A study comparing the safety profiles of aflibercept 2 mg, higher-dose aflibercept 8 mg (Eylea HD), and faricimab (Vabysmo) revealed slightly elevated rates of intraocular inflammation (IOI) with the newer agents, prompting calls for continued real-world data collection. This highlights a crucial aspect of bringing new therapies to market: understanding their long-term effects beyond the controlled environment of clinical trials.

The research, discussed by Michael S. Ip, MD, of Doheny Eye Center UCLA Arcadia, focused on intraocular inflammatory events and other side effects in patients receiving these treatments for retinal conditions. While the differences observed were described as “slightly higher” with Eylea HD and Vabysmo, the findings suggest a need for vigilant monitoring as these medications become more widely used. The study’s implications extend to patients with conditions like age-related macular degeneration (AMD) and diabetic macular edema, where these drugs are frequently employed to prevent vision loss.

Understanding Intraocular Inflammation

Intraocular inflammation, or IOI, refers to inflammation inside the eye. It can manifest in various ways, from mild discomfort and redness to more severe symptoms like pain, blurred vision, and even vision loss. The National Eye Institute (NEI) provides comprehensive information on the causes, symptoms, and treatments for various types of eye inflammation. IOI can be triggered by infection, injury, or autoimmune conditions, but in the context of these medications, it appears to be a potential side effect related to the drug itself or the injection process. Distinguishing between these causes is vital for appropriate management.

Study Details and Limitations

Dr. Ip’s comments stem from an analysis of real-world data, offering a complementary perspective to the findings from pivotal clinical trials. While the specific details of the study – including sample size, patient demographics, and precise IOI rates – weren’t fully detailed in the initial report, the emphasis on real-world data is significant. Clinical trials, while rigorous, often involve highly selected patient populations and relatively short follow-up periods. Real-world studies, by contrast, capture a broader range of patients and can reveal less common or delayed adverse events.

It’s crucial to note that the observed differences in IOI rates were described as “slight.” This suggests that the absolute risk increase may be little, and further investigation is needed to determine whether the difference is statistically significant and clinically meaningful. The study’s design – whether it was a prospective study or a retrospective chart review – would influence the strength of the conclusions that can be drawn. Retrospective studies, while quicker to conduct, are more susceptible to bias than prospective studies.

Aflibercept 8mg and Faricimab: A Closer Look

Aflibercept, initially approved as Eylea, is a vascular endothelial growth factor (VEGF) inhibitor used to treat several retinal conditions. VEGF is a protein that promotes the growth of abnormal blood vessels in the eye, contributing to vision loss in AMD and diabetic retinopathy. Faricimab (Vabysmo), a newer VEGF inhibitor developed by Genentech, also targets angiopoietin-2 (Ang-2), another protein involved in blood vessel growth and inflammation. The rationale for combining VEGF and Ang-2 inhibition is to provide a more comprehensive approach to treating these conditions.

Eylea HD, the higher-dose formulation of aflibercept, was approved with the aim of extending the time between injections, potentially reducing the treatment burden for patients. Though, the potential for increased IOI with both Eylea HD and Vabysmo raises questions about the risk-benefit profile of these newer therapies. The SPECTRUM study, mentioned by Dr. Ip, is designed to provide further real-world data on the efficacy and safety of aflibercept 8 mg in patients with diabetic macular edema and neovascular AMD. Results from this study will be crucial in informing clinical practice.

The Role of Postmarketing Surveillance

Postmarketing surveillance is a critical component of drug safety. Once a medication is approved and available to the public, ongoing monitoring is essential to identify rare or delayed adverse events that may not have been detected during clinical trials. This surveillance can take many forms, including spontaneous reporting systems (where healthcare professionals report suspected side effects), electronic health record analysis, and prospective observational studies.

The Food and Drug Administration (FDA) plays a central role in postmarketing surveillance in the United States. The FDA’s MedWatch program allows healthcare professionals and patients to report suspected drug-related adverse events. The FDA also uses other data sources, such as insurance claims data and social media monitoring, to identify potential safety signals. The agency can then take action, such as issuing warnings, updating labeling, or even withdrawing a drug from the market, if necessary.

What Comes Next: Continued Data Collection and Analysis

The findings discussed at Retina 2026 emphasize the need for continued, robust postmarketing surveillance of aflibercept 8 mg and faricimab. The SPECTRUM study will provide valuable additional data, but ongoing monitoring through other channels is also essential. Healthcare professionals should be vigilant for signs of IOI in patients receiving these medications and report any suspected adverse events to the appropriate authorities. Research is needed to identify potential risk factors for IOI and to develop strategies for mitigating this risk. This includes exploring different injection techniques, optimizing patient selection, and potentially using adjunctive therapies to reduce inflammation.

a comprehensive understanding of the long-term safety profile of these newer ophthalmic treatments will require a collaborative effort between researchers, clinicians, regulatory agencies, and patients. By prioritizing postmarketing surveillance and sharing data openly, we can ensure that these medications are used safely and effectively to preserve vision for those at risk of blindness.